G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 12.94 CNY -6.71% Market Closed
Market Cap: 5.3B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GemPharmatech Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Total Liabilities & Equity
ÂĄ2.6B
CAGR 3-Years
43%
CAGR 5-Years
90%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Liabilities & Equity
ÂĄ74.4B
CAGR 3-Years
13%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Liabilities & Equity
ÂĄ23B
CAGR 3-Years
11%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Liabilities & Equity
ÂĄ56.1B
CAGR 3-Years
9%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Liabilities & Equity
ÂĄ30.4B
CAGR 3-Years
11%
CAGR 5-Years
37%
CAGR 10-Years
38%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Liabilities & Equity
ÂĄ6.7B
CAGR 3-Years
155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.3B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
20.3 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.6B CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Total Liabilities & Equity amounts to 2.6B CNY.

What is GemPharmatech Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
90%

Over the last year, the Total Liabilities & Equity growth was 14%. The average annual Total Liabilities & Equity growth rates for GemPharmatech Co Ltd have been 43% over the past three years , 90% over the past five years .

Back to Top